title: Functional changes in dopamine D3 receptors by prenatal and neonatal exposure to an endocrine disruptor bisphenol-A in mice.
abstract: Bisphenol-A (BPA), one of the most common environmental endocrine disrupters, has been evaluated extensively for toxicity and carcinogenicity. However, little is still known about its action on the central nervous system (CNS). In the previous study, we found that prenatal and neonatal exposure to BPA markedly enhanced the rewarding effect induced by morphine. Here we found that prenatal and neonatal exposure to BPA resulted in the attenuation of dopamine D3 receptor-mediated G-protein activation by 7-OH-DPAT in the mouse limbic forebrain. This treatment also caused a significant decrease in the B(max) value of [(3)H]PD128907, a dopamine D3 receptor ligand, in this area. Under these conditions, no change in dopamine D3 receptor mRNA expression in the limbic forebrain and lower midbrain was observed by prenatal and neonatal exposure to BPA. The present data provide further evidence that prenatal and neonatal exposure to BPA leads to the reduction of functional dopamine D3 receptors without affecting the new synthesis of dopamine D3 receptors in the mouse limbic forebrain.
authors.affiliation: Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Mizuo
authors.forename: Minoru
authors.initials: M
authors.lastname: Narita
authors.forename: Takuya
authors.initials: T
authors.lastname: Yoshida
authors.forename: Michiko
authors.initials: M
authors.lastname: Narita
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001559:Benzhydryl Compounds; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology; D004622:Embryo, Mammalian; D004968:Estrogens, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D019204:GTP-Binding Proteins / Q000378:metabolism; D008032:Limbic System / Q000187:drug effects; D008297:Male; D051379:Mice; D010636:Phenols / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000187:drug effects; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D050637:Receptors, Dopamine D3; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000494:pharmacology; D000098826:Bisphenol A Compounds
chemical_list: D001559:Benzhydryl Compounds; D018491:Dopamine Agonists; D004968:Estrogens, Non-Steroidal; D019204:GTP-Binding Proteins; D010636:Phenols; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes; C493594:Drd3 protein, mouse; C006780:bisphenol A; D000098826:Bisphenol A Compounds; C031349:7-hydroxy-2-N,N-dipropylaminotetralin